Status:

RECRUITING

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Lead Sponsor:

Biocad

Conditions:

Hemophilia B

Eligibility:

MALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-002 in subjects with hemophilia В. The study will have a dose-escalation des...

Detailed Description

The study design includes ANB-002 dose escalation in at three cohorts. In Cohort 1, the subject is treated with a single dose of ANB-002 (dose 1) administered as an intravenous infusion. Follow-up for...

Eligibility Criteria

Inclusion

  • Male with hemophilia B.
  • Age ≥18 years.
  • FIX activity at screening ≤2% without FIX inhibitor.
  • ≥150 previous exposure days of treatment with FIX concentrates.

Exclusion

  • Previous gene therapy.
  • Other blood or hematopoietic disorders.
  • Positive Anti-AAV5 antibodies (for Cohorts 1-3).
  • Diagnosed HIV-infection, not controlled with anti-viral therapy.
  • Hepatitis B (for Cohorts 1-3), acute or chronic hepatitis C.
  • Any active systemic infections or recurrent infections requiring systemic therapy at screening.
  • Any other disorders associated with severe immunodeficiency.
  • Significant hepatic disorders (liver cirrhosis, liver fibrosis, etc).
  • Malignancies with remission \<5 years.

Key Trial Info

Start Date :

May 2 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2029

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT06120582

Start Date

May 2 2023

End Date

November 1 2029

Last Update

June 13 2025

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Republican Scientific and Practical Center for Radiation Medicine and Human Ecology

Homyel, Belarus, 246040

2

Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

Minsk, Belarus, 220089

3

State Autonomous Institution for Healthcare "Chelyabinsk Regional Clinical Hospital"

Chelyabinsk, Russia, 454048

4

State budgetary healthcare institution Leningrad Regional Clinical Hospital

Gatchina, Russia, 188300

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) | DecenTrialz